Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Many people have taken to going overseas to receive alternative “stem cell” treatments, some of which have not been approved in the U.S. Anecdotes abound in which patients are cured of diseases that defy conventional medicine by these treatments. But the field also has numerous patients who have not recovered—or whose deaths followed expensive procedures.